Healthcare
Abivax SA(AAVXF)
Data coverage status · 5 need attention
Quote through 2026-08-03T13:30:00Z · Stale
Quote synced 2026-08-05T22:28:27.367919Z
Daily bars through 2026-08-03 · Stale
Daily bars synced 2026-08-05T03:07:34.593709Z
Fundamentals through 2026-05-04 · Current
Fundamentals synced 2026-08-05T20:32:33.140342Z
Forecasts: Stale
Forecasts synced 2026-05-05T11:55:47.392589Z
Ownership through 2026-05-04 · Current
Ownership synced 2026-08-05T20:32:33.140342Z
Short interest: Missing
Short interest synced 2026-08-05T20:32:33.140342Z
News: Missing
News synced 0001-01-01T00:00:00Z
Company profile: Delayed
Company profile synced 2026-05-06T21:56:53.846237Z
Regular-session price
Offline$139.00
+0.00% regular session
1Y Change
+99.51%
Window
Aug 5, 2025 → Aug 3, 2026
- Market Cap
- $7.94B
- P/E
- N/M
- Non-positive trailing earnings
- 52W Range
- $10.33 - $139.00
- Volume
- 0
Investment Snapshot
Valuation, growth, profitability, catalysts, and benchmark context.
1D
0.0%
1M
+73.7%
6M
+15.0%
YTD
+17.0%
1Y
+99.5%
- Market Cap
- $7.94B
- OTC
- P/E
- N/M
- Non-positive trailing earnings
- Revenue Growth
- -100.0%
- TTM growth
- EPS Growth
- -73.6%
- TTM earnings growth
- Operating Margin
- 0.0%
- TTM profitability
- Forward P/E
- —
- Waiting on consensus EPS
- Next Earnings
- Aug 20, 2026
- In 15 days
- 52W Position
- 100%
- $10.33 - $139.00
- Volume
- 0
- 0 shares latest
- Benchmark
- +78.86 pts
- vs SPY over 1Y
- Dividend
- $0.00 annual
- No dividend date in database
Coverage: 250 bars · Aug 5, 2025 → Aug 3, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Abivax SA (AAVXF) is a Healthcare stock with listed on OTC. The stock last traded around $139.00 and up 99.5% across the available one-year price window (Aug 5, 2025 → Aug 3, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -73.6%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -73.6%, free cash flow -4.2% with operating margin 0.0% and ROIC -48.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines AAVXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.7% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
Q2 2026 was reported on May 20, 2026 with an EPS surprise of +6.2%.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at -73.6%, with operating margin around 0.0%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 20, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Delta | 1D | 5D | 20D |
|---|---|---|---|---|
Q2 2026 May 20, 2026 | +6.2% | +8.9% | +8.9% | -12.5% |
Q1 2026 Jan 17, 2026 | -10.5% | +0.0% | +0.0% | +4.0% |
Q4 2025 Dec 17, 2025 | +127.8% | +0.0% | +0.0% | +1.7% |
Benchmark Edge
AAVXF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
Mixed setup vs SPY
AAVXF is 78.86 pts ahead over the shared 1Y window.
AAVXF had 37.29 pts deeper max drawdown than SPY.
AAVXF beat SPY in 2 of 2 calendar years shown and trailed in 0.
AAVXF
+99.51%
Normalized return
SPY
+20.65%
S&P 500
Excess Return
+78.86 pts
Relative to SPY
AAVXF Max Drawdown
-46.42%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for AAVXF and SPY.
| Year | AAVXF | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +16.95% | +12.67% | +4.28 pts | AAVXF |
| 2025 | +70.59% | +9.40% | +61.19 pts | AAVXF |
Company Overview
Abivax S.A.
Other OTC
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
- Leadership
- Marc de Garidel
- IPO Date
- Sep 27, 2016
- Employees
- 69
- Street Address
- 5, rue de la Baume
- Mailing
- Paris, 75008
- Region
- Paris, FR
- Reporting Currency
- USD
- Investor Line
- 33 1 53 83 08 41
- Last Updated
- May 6, 2026
Statistics & Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- N/MNon-positive trailing earnings
- EV/EBITDA
- N/MNon-positive trailing EBITDA
- Price/Sales
- N/MNon-positive trailing revenue
- Price/Book
- 15.3
Growth
- Revenue
- -100.0%
- EPS
- -73.6%
- Free Cash Flow
- -4.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -165.2%
- ROIC
- -48.0%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 4.27
Ownership & Float
- Float
- 45.57M
- Insider Owned
- 5.3%
- Institutional Owned
- 49.4%
Earnings Reports
Latest News
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.